Page 17 - ebook
P. 17
고형암 항암치료 환자의 부작용 관리 Nausea and Vomiting
Classification Agent
Parenteral Low emetic risk Mitomycin
Mitomycin prelocalyceal solution
Mitoxantrone
Mogamulizumab
Moxetumomab
Necitumumab
Olaratumab
Omacetaxine
Paclitaxel
Paclitaxel-albumin
Pemetrexed
Pentostatin
Polatuzumab vedotin
Pralatrexate
Romidepsin
Tafasitamab-cxix
Tagraxofusp
Talimogene laherparepvec
Thiotepa
Tisagenlecleucel
Topotecan
Ziv-aflibercept
Minimal emetic risk Alemtuzumab
Atezolizumab
Avelumab
Asparaginase
Bevacizumab
Vleomycin
Blinatumomab
Bortezomib
Cetuximab
Cemiplimab
Cladribine
Cytarabine < 100 mg/m 2
Daratumumab
Daratumumab and hyluronidase-fihg
Decitabine
Denileukin diftitox
Dexrazosane
Duvalumab
Elotuzumab
Fludarabine
Ipilimumab
Lupatercept-aamt
Methotrexate ≤ 50 mg/m 2
Nelarabine
17